Another interesting topic discussed at the Feb 23 earnings call, rPFS is not a strong indicator of overall survival (OS). OS is what i would want as a patient and in my opinion what would determine the success of the product along with a point of difference (2 doses vs 6 doses) from current market product (Pluvicto). So with that being said, whatever the rPFS data is from TLX591 the question would be is this data going to determine the success of the product...probably not.
Transcript below -
Understanding Telix, page-712
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.13 |
Change
-0.340(1.75%) |
Mkt cap ! $6.401B | |||
| Open | High | Low | Value | Volume |
| $19.41 | $19.46 | $18.81 | $121.0M | 6.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7316 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.13 | 6814 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |